Cardiovascular history, abiraterone acetate, and 6-month mortality rates

In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …

LAST CHANCE to participate in our current survey

By late yesterday nearly 600 men had completed our recent survey and most of them had expressed some degree of interest in participating in the quality of life trial we will be initiating soon. Again, thanks to all of you who have done that. … READ MORE …

Do men on AS need their own support groups?

Howard Wolinsky is a long-time prostate cancer patient who has been on active surveillance (AS) since his diagnosis in 2010, when one of his doctors described him as a “poster child” for active surveillance. … READ MORE …

Modern prostate cancer imaging: application of the right scan at the right time

A new “opinion” article in the Journal of Clinical Oncology this week has addressed the complex issue of how best to think about (a) how we are regulating use of and (b) how we are applying new forms of imaging technique in the management of prostate cancer … READ MORE …

The treatment of mCRPC with a combination of docetaxel + enzalutamide

We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …

PLEASE consider completing our recent survey!

So just over 300 patients have already completed the survey that we put up on line last Friday. Thanks to all of you who have done that. And we’d really like to see if we can get to a total of something like 750 “with a little help from our friends”. … READ MORE …

A new study (and new technology) about quality of life and prostate cancer

Prostate Cancer International and two of its partners — CancerLife and the John Wayne Cancer Institute in Santa Monica, CA — are soon going to be looking for men to participate in a new clinical trial about quality of life and living with prostate cancer. … READ MORE …